Related Experiment Video

Updated: Sep 22, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

286

Oncology stewardship in acute myeloid leukemia

Madeleine A Ochs1, Bernard L Marini1,2, Anthony J Perissinotti1

  • 1Department of Pharmacy Services and Clinical Pharmacy, Michigan Medicine, 1540 E. Hospital Dr, Ann Arbor, MI, 48109, USA.

Annals of Hematology
|May 26, 2022
PubMed

Insights

Novel agents are changing acute myeloid leukemia (AML) treatment, but their optimal use is unclear. This review evaluates five controversial AML agents using oncology stewardship principles to guide their place in therapy.

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • The treatment landscape for acute myeloid leukemia (AML) has been significantly altered by the introduction of numerous novel therapeutic agents.
  • Uncertainty exists regarding the optimal integration of these new agents into clinical practice due to limited national guideline recommendations and varying study designs preceding market approval.
  • The high cost associated with novel therapies necessitates careful consideration of their value and place in patient treatment regimens.

Purpose of the Study:

  • To critically assess the efficacy and safety profiles of five controversial novel agents used in acute myeloid leukemia (AML) treatment.
  • To explore the application of oncology stewardship principles in defining the optimal therapeutic role for these agents.
  • To provide practical examples of how stewardship can inform decision-making for novel AML therapies, balancing clinical benefit with cost-effectiveness.

Main Methods:

  • Comprehensive literature review focusing on efficacy and safety data for five specific novel agents in acute myeloid leukemia (AML).
  • Application of established oncology stewardship principles to analyze the evaluated data.
  • Case examples illustrating the integration of stewardship practices in determining the appropriate use of these agents.

Main Results:

  • Efficacy and safety data for five controversial novel agents in acute myeloid leukemia (AML) were critically evaluated.
  • The analysis highlighted variability in clinical benefit and toxicity across different agents and patient populations.
  • Stewardship principles provided a framework for assessing the value and appropriate utilization of these therapies.

Conclusions:

  • A critical evaluation of novel agents, guided by oncology stewardship, is essential for optimizing acute myeloid leukemia (AML) treatment.
  • Stewardship practices can help navigate the complexities of integrating new therapies, ensuring appropriate use and cost-effectiveness.
  • Further research and guideline development are needed to solidify the role of these agents in AML management.
Keywords:
Acute myeloid leukemiaFinancial toxicityNovel agentsOncology stewardship

More Related Videos

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.2K
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.7K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.2K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.3K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
516